Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis
Molecular Diversity · 30.06.2026 · 30 (6) · 9853-9874
DOI: 10.1007/s11030-026-11639-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Diversity, online erschienen am 30.06.2026. Verfasst von Borakha Bura Gohain und 3 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam, 786004, India. Hauptthemen laut MEDLINE: Drug Repositioning, Molecular Dynamics Simulation, Antitubercular Agents, Genomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 101 Literaturangaben. Gefördert von: DST PURSE, Department of Health Research (DHR), Ministry of Health & Family Welfare, Government of India..
Abstract (Originalsprache)
Female genital tuberculosis (FGTB) often remains untreated because many patients show no clear symptoms or present with vague clinical symptoms. Poor reproductive outcomes and prolonged treatment are usually the results of this delay in detection. Current TB therapies are costly and toxic, especially for strains of the disease that are resistant to several drugs. These drawbacks highlight the urgent need for safer and more effective treatment options. Computational drug discovery approaches targeting uterine TB remain limited, and essential pathogen-specific proteins non-homologous to humans are underexplored. This work identified GMP synthase as an important and specific target in Mycobacterium tuberculosis using subtractive genomics and drug repurposing. To improve specificity, targets that are similar to commensal and human proteins were discarded. 2619 FDA-approved drugs were virtually screened, and probenecid was found to be a probable choice. Quantum chemical analysis confirmed the robust binding and stable interactions of probenecid with the target. Molecular dynamics simulations and RMSD- Rg -based- Free Energy Landscape (FEL), along with PCA- based- Free Energy Landscape (FEL), confirmed the stability of the protein-ligand complex, and molecular docking identified favorable binding patterns. Probenecid inhibited M. tuberculosis H37Rv at a minimum inhibitory concentration (MIC) of 50 µg/mL, according to in vitro studies, while isoniazid and rifampicin had MICs of 0.20 µg/mL and 0.25 µg/mL, respectively. However, Probenecid's well-established safety profile and pharmacokinetic characteristics indicate that localized administration via a liposomal vaginal formulation may achieve therapeutic concentrations at the infection site while lowering systemic exposure, even though it is less effective than first-line medications. Future study will focus on mucosal safety, local pharmacokinetics, and formulation development. Overall, our findings highlight the usefulness of combining subtractive genomics, computational modeling, and experimental validation in tuberculosis drug discovery and indicate the possibility of repurposing probenecid for FGTB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam, 786004, India.
- Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam, 786004, India. s_rajkhowa@dibru.ac.in.
- Department of Pharmaceutical Sciences, Dibrugarh University, Dibrugarh, Assam, 786004, India.
- Department of Chemistry, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
Förderung
- DST PURSE
- Department of Health Research (DHR), Ministry of Health & Family Welfare, Government of India.
Zitieren
APA
Bura Gohain, B., Rajkhowa, S., Mazumder, B., & Zaki, M. E. A. (2026). Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis. Molecular Diversity, 30(6), 9853-9874. https://doi.org/10.1007/s11030-026-11639-7
Vancouver
Bura Gohain B, Rajkhowa S, Mazumder B, Zaki MEA. Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis. Molecular Diversity. 2026;30(6):9853-9874. doi:10.1007/s11030-026-11639-7
BibTeX
@article{BuraGohain2026,
author = {Bura Gohain, Borakha and Rajkhowa, Sanchaita and Mazumder, Bhaskar and Zaki, Magdi E A},
title = {Integrative subtractive genomics and molecular dynamics-based approach for drug repurposing against female genital tuberculosis},
journal = {Molecular Diversity},
year = {2026},
volume = {30},
number = {6},
pages = {9853--9874},
doi = {10.1007/s11030-026-11639-7}
}
EUVIMED